The Interpretation of Sequence Variants in Myeloid Neoplasms
- PMID: 34155503
- DOI: 10.1093/ajcp/aqab039
The Interpretation of Sequence Variants in Myeloid Neoplasms
Abstract
Objectives: To provide an overview of the challenges encountered during the interpretation of sequence variants detected by next-generation sequencing (NGS) in myeloid neoplasms, as well as the limitations of the technology with the goal of preventing the over- or undercalling of alterations that may have a significant effect on patient management.
Methods: Review of the peer-reviewed literature on the interpretation, reporting, and technical challenges of NGS assays for myeloid neoplasms.
Results: NGS has been integrated widely and rapidly into the standard evaluating of myeloid neoplasms. Review of the literature reveals that myeloid sequence variants are challenging to detect and interpret. Large insertions and guanine-cytosine-heavy areas prove technically challenging while frameshift and truncating alterations may be classified as variants of uncertain significance by tertiary analysis informatics pipelines due to their absence in the literature and databases.
Conclusions: The analysis and interpretation of NGS results in myeloid neoplasia are challenging due to the varied number of detectable gene alterations. Familiarity with the genomic landscape of myeloid malignancies and knowledge of the tools available for the interpretation of sequence variants are essential to facilitate translation into clinical and therapy decisions.
Keywords: Hematopathology; Molecular diagnostics; Myeloid neoplasms; Next-generation sequencing.
© American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Next-generation sequencing-based panel testing for myeloid neoplasms.Curr Hematol Malig Rep. 2015 Jun;10(2):104-11. doi: 10.1007/s11899-015-0256-3. Curr Hematol Malig Rep. 2015. PMID: 25933675 Review.
-
Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.Arch Pathol Lab Med. 2017 Jun;141(6):759-775. doi: 10.5858/arpa.2016-0547-RA. Epub 2017 Mar 9. Arch Pathol Lab Med. 2017. PMID: 28557600
-
The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.Am J Clin Pathol. 2020 Apr 15;153(5):639-645. doi: 10.1093/ajcp/aqz203. Am J Clin Pathol. 2020. PMID: 31875888
-
Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.Blood Cancer J. 2018 Nov 12;8(11):113. doi: 10.1038/s41408-018-0148-6. Blood Cancer J. 2018. PMID: 30420667 Free PMC article. Review.
-
Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.Leukemia. 2018 Aug;32(8):1874-1878. doi: 10.1038/s41375-018-0193-y. Epub 2018 Jun 29. Leukemia. 2018. PMID: 29959414 Free PMC article. No abstract available.
Cited by
-
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets.Blood. 2023 May 4;141(18):2214-2223. doi: 10.1182/blood.2022018825. Blood. 2023. PMID: 36652671 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources